Wellfully (ASX:WFL) - CEO, Paul Peros
CEO, Paul Peros
Source: Cosmetics Design Asia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Wellness group OBJ has announced it had only secured offers for 37 per cent of new shares on offer during a recent capital raise
  • OBJ announced last month it was aiming to raise between $3 million and $4.5 million via an entitlement offer and placement
  • Shareholders were offered one new share for every three already held under the offer, with the new shares prices at 10 cents each
  • In the end, OBJ received applications for over 11 million new shares, raising $1.12 million via the offer
  • Shares in OBJ have been suspended since November 2019, and last traded for 1.2 cents each

Wellness group OBJ (OBJ) isn’t looking too well, after only securing offers for 37 per cent of new shares offered during a recent capital raise.

OBJ first announced the non-renounceable entitlement offer on July 10, as well as a proposed placement.

Under the entitlement offer, shareholders were offered one new share for every three already held, with the new shares priced at 10 cents each.

While under the placement, 15 million shares would be sold at the same price, but to sophisticated and professional investors.

When the two equity raises were combined the company was hoping to raise up between $3 million and $4.5 million.

The company today revealed it had closed the entitlement offer with a shortfall, as only 37 per cent of eligible shareholders subscribed for new shares.

This means OBJ will walk away with $1.12 million, well below the minimum $3 million target.

The company’s board of directors and Lead Manager, CPS Capital Group, will now place the shortfall shares to professional and sophisticated investors.

There are over 18 million new shares still on offer and they will be placed at the board and CPS Capital’s discretion.

Meantime, shares in OBJ have been suspended since November 2019, and last traded for 1.2 cents each.

OBJ by the numbers
More From The Market Online

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…

Telix Pharmaceuticals granted US-FDA fast track designation for brain cancer detection

Telix Pharmaceuticals has been granted Fast Track designation by the FDA for its brain cancer imaging…

Atomo Diagnostics orders HIV self-test kits for third world countries

Atomo Diagnostics (ASX:AT1), has put in a purchase order from Viatris Healthcare for HIV self-tests, valued…

Imugene expands study for bile tract cancer patients

Imugene will be expanding its trial to treat gastrointestinal cancers - including bile tract cancer -…